A study of the investigational drug PF-07220060 together with Letrozole compared to Letrozole alone in postmenopausal women
Résumé de l'étude
The aim of this study is to investigate the effect of the investigational drug PF-07220060 plus Letrozole compared to the sole intake of Letrozole without PF-07220060 for the treatment of breast cancer. Participants will be randomly assigned (like flipping a coin) either to the treatment (PF-07220060 plus Letrozole) or to Letrozole alone. Both PF-07220060 and Letrozole will be taken orally. PF-07220060 will be taken twice daily for 14 days. Letrozole will be taken once daily for 14 days. Participants will have a pre-screening period of up to 28 days. If found eligible, they will receive a study treatment for 14 days and will then be invited for a follow-up approximately 28 days after the last dose. For all study participants, at least one biopsy will be performed during the study. A biopsy is the removal of cells or tissue for examination. A biopsy will be performed on all study participants on day 14. During the study, additional safety assessments, including blood draws and surveys by onsite staff, will be conducted.
(BASEC)
Intervention étudiée
In the trial: Arm A/Experimental/PF-07220060 plus Letrozole
PF-07220060 will be taken orally in tablet form twice daily for 14 days. Letrozole will be taken orally in tablet form once daily for 14 days.
Active comparator: Arm B/Control/Letrozole
Letrozole will be taken orally once daily for 14 days.
(BASEC)
Maladie en cours d'investigation
Breast cancer
(BASEC)
Postmenopausal women with histologically confirmed HR-positive and HER2-negative breast cancer (after local assessment) Documented estrogen receptor (ER) and/or progesterone receptor (PR) positive disease by IHC or ISH Participants must have a KI-67 score of >/= 10 % with unilateral, invasive T1c-T4c, N0-N2, and M0 breast cancer Participants must be willing and able to undergo a biopsy at baseline and on day 14 of the study, and they must have an ECOG score of 0 or 1. Participants must be eligible for breast cancer treatment and must not have received systemic therapy (e.g., chemotherapy, hormone therapy), radiation, surgery, or an investigational drug within 2 weeks prior to the collection of the diagnostic tissue sample, nor have used hormone replacement therapy (HRT) or another estrogen-containing medication (including vaginal estrogen). (BASEC)
Critères d'exclusion
A prior systemic therapy, radiation, surgery, investigational therapy for breast cancer Certain conditions in the past 6 months, e.g.: myocardial infarction, severe unstable angina pectoris, coronary/peripheral bypass surgery, symptomatic heart failure (New York Heart Association Class III or IV), cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism, or other clinically significant episode of thromboembolism Laboratory abnormalities outside the parameters specified in the protocol (BASEC)
Lieu de l’étude
Aarau, Bâle, Berne, Lausanne, Autre
(BASEC)
Baden
(BASEC)
Sponsor
Pfizer Inc 66 Hudson Boulevard East New York NY 10001 USA Sponsor’s representative in Switzerland: Martina Knecht Maier Pfizer AG Zürich
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Martina Knecht Maier
+41 78 615 62 56
martina.knechtmaier@clutterpfizer.comPfizer AG Schärenmoosstrasse 99 8052 Zürich Schweiz
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale d'éthique du Vaud
(BASEC)
Date d'approbation du comité d'éthique
16.12.2024
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
C4391025/AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER IN THE NEOADJUVANT SETTING (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible